That’s what at least one analyst over at London-based Datamonitor thinks. “Pharma is cash rich and has not taken on significant debt,” said Chris Phelps, head of company analysis for Datamonitor in a press release. “As a result, the credit crunch will actually play out as a net positive for an industry much in need of good news,” he said. As for biotech, Phelps said, “the outlook is far from positive.” Biotech will be increasingly forced to look to big pharma for funding, and that will shift the balance of power in big pharma’s favor, he said.
Advertisement
Subscribe in RSS Reader
